Click here if you are having trouble viewing this message.

October newsletter

In this newsletter:
- What needs to be done to facilitate the adoption of ATMPs into the NHS?
- How can the industry drive the uptake of automation in manufacturing and development?
- What is the cost of implementing an outcomes-based managed entry agreement for an advanced therapy?

This month we have seen tangible evidence of the industry working together to support the development and adoption of advanced therapies, making practical steps forward in a number of areas.

We bought together expert stakeholders to address how we can facilitate the adoption of ATMPs into the NHS and discuss the role of the Advanced Therapy Treatment Centre network in driving adoption of ATMPs. A summary of outcomes from the workshop is now available.

Phacilitate have also published the conclusions reached at the Automation Special Interest Group on how to drive automation in cell and gene therapy processing and manufacturing. We were pleased to be one of the expert stakeholders that took part.

We have also looked at how patient access can be enabled by implementing outcomes-based managed entry agreements when there is uncertainty in the clinical data. The case study can be viewed on our website.

Finally we would like to welcome Sir Bruce Keogh, Professor Uta Griesenbach and Hilary Newiss to the CGT Catapult Board.

Share this email on social media

News

Recommendations to tackle key challenges in ATMP adoption
Expert stakeholders from industry, payers, NHS and patient groups came together to explore how the Advanced Therapy Treatment Centre network can drive adoption of cell and gene therapies.
Summary of findings

Quantifying the cost of implementing outcomes-based managed entry agreements
In first of its kind research, our health economics team quantified the cost of implementing an outcomes-based managed entry agreement in acute lymphoblastic leukaemia.
Read the case study

Outcomes from Automation special interest group published
Phacilitate have published a report following the 2018 Automation Special Interest Group. The report summarises the onsite discussions and findings, and makes recommendations for how to move forward.
Download the report

New Board members strengthen CGT Catapult leadership team
Sir Bruce Keogh, Professor Uta Griesenbach and Hilary Newiss have all been appointed as Non-Executive Directors and will join current Board members supporting the activities of CGT Catapult.
Read the press release

Where to meet the team

Seminar day @ University of Nottingham
Are you based in the Midlands and involved in cell and gene therapy research, development or manufacturing? Want to learn how we can accelerate your advanced therapy research towards the clinic? We are at the University of Nottingham on 27 November to meet advanced therapy researchers and industry to answer your questions!

Tuesday 27 November 2018
10:00 - 16:00

Register for free

+44 (0) 203 728 9500
12th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT

The Cell and Gene Therapy Catapult takes your data very seriously, you can read how we may use it in our privacy policy. If you no longer want to hear from us unsubscribe here.